Abstract:Lung cancer remains the leading cause of cancer death in the United States. One reason for this high mortality is that >40% of cases are diagnosed at a late stage, where the 5-year survival rate is low. Liquid biopsy molecular testing has transformed lung cancer care through the identification of driver mutations when tissue is inaccessible. It also has promise as a tool in early detection and diagnosis, thereby reducing mortality. The existing paradigm for lung cancer screening and diagnosis includes low dose CT (LDCT) scans and tissue biopsy. LDCT scans yield a visualization of lung abnormalities. However, many of these abnormalities are difficult to characterize and next steps are often unclear to physicians. One option is to continue to monitor the patient, which may risk a delay in cancer treatment. Up to 15% of all individuals who are put on a monitoring regime will ultimately be diagnosed with lung cancer. A second option is to biopsy the nodule, which risks unnecessary invasive procedures and expenses to patients. 42-62% of indeterminate nodules detected by LDCT are found to be benign after biopsy. Furthermore, 15% of transthoracic needle biopsies result in complications. Genece Health aims to decrease uncertainty in cancer diagnosis and improve patient outcomes through a minimally invasive liquid biopsy assay that detects the presence of lung cancer. The technology utilizes a proprietary algorithm that leverages machine learning models to detect lung cancer signals in low-pass whole genome sequencing (LP-WGS) of patient cfDNA isolated from plasma. To establish assay performance, 50 clinical lung cancer samples from a commercial biobank, and 100 presumed normal samples were collected in Streck cfDNA BCT Devices. Following cfDNA extraction from plasma, LP-WGS was performed. Sequencing data was then processed to generate fragment end-motif and size (FEMS) and fragment coverage data that was input into Genece Health's proprietary machine learning classifier to generate a final cancer prediction score. In addition, a limit of detection was determined using three late-stage lung cancer samples, with tumor fractions estimated using whole exome sequencing and ichorCNA scores. Our results show >80% specificity, >90% sensitivity, and a limit of detection of <1% tumor fraction. Through this testing, we demonstrate the assay's ability to detect lung cancer across various lung cancer stages, including early stage disease, and histologies. Genece has developed a highly sensitive and specific lung cancer detection liquid biopsy assay. We present this assay as a cost-effective approach to discriminate between benign and malignant nodules identified by LDCT. In addition, this assay has the potential to be applied across the cancer care continuum. For example, future work will involve characterizing the assay's ability to be applied in early cancer screening. Citation Format: Bryan Leatham, Michael Salmans, Molly Smith, Mengchi Wang, Andrew Carson, Kristin Fathe, Byung In Lee. A novel liquid biopsy lung cancer detection method using a coverage and fragment end motif machine learning analysis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 3448.

Early detection of cancer using cell-free DNA (cfDNA) size analysis on a multiplexed amplicon-based next-generation sequencing (NGS) platform.

392P Integrating Fragmentomic Features for Non-Invasive Early Detection of Colorectal Advanced Adenoma and Adenocarcinoma

Early cancer detection using low-coverage whole-genome sequencing of cell-free DNA fragments.

Ultra-short Cell-Free DNA Fragments Enhance Cancer Early Detection in a Multi-Analyte Blood Test Combining Mutation, Protein and Fragmentomics.

Abstract 2290: Integration of cell-free DNA end motifs and fragment lengths can improve identification of active genes in liquid biopsies

Integration of Cell-Free DNA End Motifs and Fragment Lengths Can Identify Active Genes in Liquid Biopsies

Abstract 4950: Applying fragmentomics profiles of plasma cell-free DNA for breast cancer detection

Analysis of a Cell-Free DNA-based Cancer Screening Cohort Links Fragmentomic Profiles, Nuclease Levels, and Plasma DNA Concentrations

Fragment Length of Circulating Tumor DNA

Multi-dimensional cell-free DNA-based liquid biopsy and early detection of gastric cancer.

Early Cancer Detection Using Multi-Omic Approach Including Epigenetic Signal from Ultra-Small Fragments.

Abstract 3353: Cell-free DNA (cfDNA) fragmentation profiles linked to copy number alteration analysis allows for early colorectal cancer detection

Abstract 3448: A novel liquid biopsy lung cancer detection method using a coverage and fragment end motif machine learning analysis

Characterization of Fragment Sizes, Copy Number Aberrations and 4‐mer End Motifs in Cell‐free DNA of Hepatocellular Carcinoma for Enhanced Liquid Biopsy‐based Cancer Detection

Evaluating the quantity, quality and size distribution of cell-free DNA by multiplex droplet digital PCR

Distinct Features of Plasma Ultrashort Single-Stranded Cell-Free DNA as Biomarkers for Lung Cancer Detection

Multi-Dimensional Cell-free DNA Fragmentomic Assay for Detection of Early-Stage Lung Cancer

Abstract 6258: Inference of gene expression using fragmentation patterns from targeted high-depth sequencing of cell-free DNA

Perspective on New Cell-Free DNA Technologies for Early Cancer Detection.

Detection and characterization of lung cancer using cell-free DNA fragmentomes

Increased Detection of Circulating Tumor DNA by Short Fragment Enrichment